Lumida
/MRK
⌘K
Merck & Co Inc

Merck & Co Inc

MRK
$143.93USD-0.54%-0.78 today

MARKET CAP

355.1B

P/E (TTM)

40.4x

FWD P/E

DAY RANGE

$144 – $146

52W RANGE

$78
$157

AI Summary

Stalk
StalkMedium

MRK remains structurally bullish, trading above its rising 50- and 200-day SMAs, but short-term momentum has weakened as price sits below the 9- and 20-day EMAs and RSI approaches oversold. Execution is deferred; we will stalk for a pullback into the key support zone around the 50-day SMA before engaging the long side.

  • Robust pipeline: 20+ product launches with $70B revenue potential.
  • INTerpath-001 melanoma vaccine trial showed survival improvements.
  • Keytruda exclusivity ends, risking $8.4B annual sales decline.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$48.7B$59.3B$60.1B$64.2B$65.0B
YoY %+17.3%+21.7%+1.4%+6.7%+1.3%
P / Sales4.0x4.8x4.8x3.9x4.1x
EV / Sales5.2x5.6x5.8x4.8x5.1x
Gross Profit, Adj.$35.1B$41.9B$44.0B$49.0B$48.6B
YoY %+25.7%+19.4%+5.1%+11.3%-0.7%
Margin %72.0%70.6%73.2%76.3%74.8%
EV / Gross Profit7.2x8.0x8.0x6.3x6.9x
EBITDA, Adj.$16.4B$22.2B$6.8B$24.7B$27.9B
YoY %+81.7%+35.2%-69.2%+262.1%+13.0%
Margin %33.7%37.4%11.4%38.5%43.0%
EV / EBITDA15.5x15.0x51.4x12.6x11.9x
EBIT$12.5B$17.9B$2.4B$19.9B$21.2B
YoY %+152.1%+43.1%-86.9%+745.5%+6.6%
Margin %25.7%30.3%3.9%31.0%32.6%
EV / EBIT20.2x18.6x148.9x15.6x15.7x
Net Income$13.0B$14.5B$365.0M$17.1B$18.3B
YoY %+84.6%+11.3%-97.5%+4589.6%+6.6%
Net Margin26.8%24.5%0.6%26.7%28.1%
EPS (GAAP)$5.14$5.71$0.14$6.74$7.28
YoY %+84.9%+11.1%-97.5%+4714.3%+8.0%